Curis, Inc. (NASDAQ:CRIS - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $10.49 and traded as high as $17.49. Curis shares last traded at $16.50, with a volume of 40,389 shares trading hands.
Wall Street Analyst Weigh In
Separately, HC Wainwright decreased their price target on Curis from $51.00 to $26.00 and set a "buy" rating for the company in a research report on Friday, February 9th.
View Our Latest Stock Report on Curis
Curis Trading Down 5.6 %
The stock has a market capitalization of $91.83 million, a price-to-earnings ratio of -1.74 and a beta of 3.72. The stock has a 50-day simple moving average of $10.82 and a 200 day simple moving average of $10.53.
Curis (NASDAQ:CRIS - Get Free Report) last announced its quarterly earnings data on Thursday, February 8th. The biotechnology company reported ($2.03) EPS for the quarter, missing analysts' consensus estimates of ($1.91) by ($0.12). Curis had a negative return on equity of 169.22% and a negative net margin of 473.04%. The business had revenue of $2.70 million for the quarter, compared to analyst estimates of $2.95 million. During the same quarter in the previous year, the business posted ($2.40) earnings per share. Sell-side analysts expect that Curis, Inc. will post -5.92 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Curis
Several institutional investors have recently made changes to their positions in the company. a16z Perennial Management L.P. bought a new position in shares of Curis in the 4th quarter valued at approximately $85,000. Dynamic Technology Lab Private Ltd raised its stake in shares of Curis by 40.2% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 40,700 shares of the biotechnology company's stock valued at $97,000 after acquiring an additional 11,660 shares in the last quarter. Swiss National Bank raised its stake in shares of Curis by 7.9% in the 1st quarter. Swiss National Bank now owns 162,500 shares of the biotechnology company's stock valued at $387,000 after acquiring an additional 11,900 shares in the last quarter. Engineers Gate Manager LP bought a new position in shares of Curis in the 1st quarter valued at approximately $32,000. Finally, Geode Capital Management LLC raised its stake in shares of Curis by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 813,257 shares of the biotechnology company's stock valued at $447,000 after acquiring an additional 15,425 shares in the last quarter. 29.97% of the stock is currently owned by institutional investors and hedge funds.
About Curis
(
Get Free Report)
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Featured Articles
Before you consider Curis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curis wasn't on the list.
While Curis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
